Letrox 150

Package leaflet: Information for the user

Letrox 50, 50 micrograms, tablets
Letrox 75 micrograms, 75 micrograms, tablets
Letrox 100, 100 micrograms, tablets
Letrox 125 micrograms, 125 micrograms, tablets
Letrox 150, 150 micrograms, tablets
Levothyroxinum natricum
Please read all of this leaflet carefully before taking this medicine, because it contains
important information for you.

• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor or pharmacist.
• This medicine has been prescribed for you personally. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
• If you experience any side effects, including any not listed in this leaflet, tell your doctor or pharmacist. See section 4.

Contents of the leaflet

1. What Letrox is and what it is used for
2. What you need to know before taking Letrox
3. How to take Letrox
4. Possible side effects
5. How to store Letrox
6. Contents of the pack and other information

1. What Letrox is and what it is used for

Letrox is a medicine containing the thyroid hormone levothyroxine as the active substance. It has the same action as the hormone naturally produced by the body.
The purpose of treatment with Letrox is to replace deficient thyroid hormone and (or) to alleviate disorders of thyroid function.
Letrox is used:

• To replace thyroid hormones in hypothyroidism.
• To prevent recurrence of goitre (enlargement of the thyroid gland) after surgical treatment in patients with normal thyroid function.
• In the treatment of benign goitre in patients with normal thyroid function.
• As an adjunct in the treatment of hyperthyroidism, in combination with antithyroid drugs (medicines that suppress thyroid function), after normal thyroid function has been achieved.
• In the treatment of malignant thyroid tumours, particularly after surgical removal of the thyroid gland, to suppress tumour growth and to replace deficient thyroid hormones.
• In diagnostic tests assessing thyroid function (thyroid suppression test).

Letrox is indicated for use in all age groups.

2. Important information before using Letrox

When not to use Letrox

• If the patient is allergic to sodium levothyroxine or any of the other ingredients of this medicine (listed in section 6).
• If the patient has any of the following diseases or conditions:
  • untreated hyperthyroidism
  • adrenal insufficiency and the patient is not receiving adequate replacement therapy
  • untreated pituitary insufficiency, if it leads to adrenal cortical failure requiring treatment
  • acute myocardial infarction
  • acute myocarditis
  • acute inflammation of all layers of the heart wall (acute pericarditis).

During pregnancy, Letrox must not be taken at the same time as drugs that suppress thyroid function (so-called antithyroid drugs) (see also section "Pregnancy, breastfeeding and fertility").

Warnings and precautions

Before starting treatment with Letrox, discuss this with your doctor if the patient has adrenal insufficiency.

Medical history regarding other disorders

Before starting treatment with Letrox, the doctor should exclude or treat the following diseases or conditions:

• coronary heart disease
• chest pain with pressure (angina pectoris)
• high blood pressure (hypertension)
• pituitary and/or adrenal insufficiency
• autonomous thyroid nodules producing thyroid hormones uncontrollably.

Before performing a so-called thyroid suppression test to assess thyroid function, the above-mentioned conditions should be excluded or treated by the physician. The exception is autonomous thyroid function, as the test is used, among other things, to identify it.

Particular caution is required when taking Letrox:

• in patients with a history of myocardial infarction, coronary heart disease, weakened heart muscle, cardiac arrhythmias (tachycardia), non-acute myocarditis, or long-standing hypothyroidism. In such cases, excessive concentrations of thyroid hormones in the blood should be avoided. Thyroid hormone levels should be monitored more frequently. If mild symptoms of hyperthyroidism occur related to taking Letrox, discuss this with your doctor (see section 4 "Possible side effects").
• in patients with hypothyroidism due to pituitary insufficiency. In cases of coexisting adrenal cortical failure, the doctor should initiate treatment for this first, as acute adrenal crisis (Addisonian crisis) may occur.
• if there is suspicion of autonomously functioning thyroid tissue. Before starting treatment, the doctor will recommend additional tests to evaluate thyroid function.
• in postmenopausal women at increased risk of bone loss (osteoporosis). The treating physician should monitor thyroid function much more frequently to avoid excessive serum thyroid hormone concentrations and ensure the use of the lowest effective dose.
• in patients with diabetes. For further information, see section "Letrox with other medicines".
• in patients treated with anticoagulant drugs (e.g. dicoumarol) and drugs affecting the thyroid (e.g. amiodarone, tyrosine kinase inhibitors [drugs used in cancer treatment], salicylates, and high doses of furosemide). For further information, see section "Letrox with other medicines".
• in patients receiving sevelamer. The treating physician will recommend monitoring blood TSH levels to assess the effectiveness of levothyroxine therapy (see also: "Letrox with other medicines").
• if the patient has ever had epilepsy, due to an increased risk of seizures.
• if the patient experiences an allergic reaction (see section 4. "Possible side effects"). Seek immediate medical advice from a doctor or healthcare professional, or go immediately to the nearest hospital emergency department.
• if laboratory tests to measure thyroid hormone levels are to be performed, the patient should inform the doctor or laboratory staff about current or recent biotin intake (also known as vitamin H, vitamin B7, or vitamin B8). Biotin may interfere with laboratory test results. Depending on the type of test, results may be falsely elevated or falsely decreased due to biotin intake. The doctor may advise the patient to discontinue biotin before laboratory testing. Also note that other products taken by the patient, such as multivitamin preparations or supplements for hair, skin, and nails, may also contain biotin. This may affect laboratory test results. If the patient takes such products, they should inform the doctor or laboratory staff (refer to information in section "Letrox with other medicines").

Improper use

Letrox must not be used for weight reduction. In patients with normal serum thyroid hormone concentrations, additional intake of thyroid hormones will not lead to weight loss. Taking extra thyroid hormones or increasing the dose without specific medical advice may cause severe, even life-threatening, adverse effects, especially when combined with other weight-reducing drugs.

Changing treatment

When switching from Letrox to another levothyroxine-containing medicine, thyroid function imbalance may occur. If there are any questions regarding such a switch, discuss them with your doctor. Patients should be closely monitored (clinically and biologically) during the transition period. Inform your doctor if any adverse effects occur, as this may indicate the need for dose adjustment (increase or decrease).

Elderly patients

In elderly patients (especially those with heart problems), the dose should be increased cautiously, and patients should undergo more frequent medical check-ups.

Children and adolescents

When starting levothyroxine treatment in preterm infants with very low birth weight, blood pressure should be monitored regularly, as sudden drops in blood pressure (so-called circulatory collapse) may occur (see section 4 "Possible side effects").

Letrox with other medicines

Inform your doctor or pharmacist about all medicines currently or recently taken, as well as any medicines planned for future use.

Letrox affects the action of the following medicinal substances and drug groups:

• Antidiabetic drugs (drugs reducing blood glucose such as metformin, glimepiride, glibenclamide, and insulin): In diabetic patients, blood glucose levels should be monitored regularly, especially at the beginning and after completion of thyroid hormone therapy. If necessary, the doctor may adjust the dose of the antidiabetic drug, as levothyroxine may reduce its effectiveness.
• Coumarin derivatives (anticoagulants): When Letrox is taken concomitantly with coumarin derivatives (e.g. dicoumarol), blood coagulation parameters should be monitored regularly. If necessary, the doctor may adjust the dose of the anticoagulant, as levothyroxine may enhance its effect.

The following medicines may affect the action of Letrox:

• Ion-exchange resins: Medicines used to lower blood lipid levels (e.g. cholestyramine, colestipol) or to reduce high blood potassium levels (calcium or sodium polystyrene sulfonate) should be taken 4 to 5 hours after taking Letrox. Otherwise, these drugs may inhibit intestinal absorption of levothyroxine and thereby reduce its efficacy.
• Proton pump inhibitors (PPIs): Proton pump inhibitors (such as omeprazole, esomeprazole, pantoprazole, rabeprazole, and lansoprazole), used to reduce stomach acid production, may inhibit intestinal absorption of levothyroxine and thereby reduce its efficacy. If the patient is taking levothyroxine during PPI treatment, the doctor should monitor thyroid function and adjust the Letrox dose if necessary.
• Sevelamer and lanthanum carbonate: Sevelamer and lanthanum carbonate (used to lower elevated serum phosphate levels in dialysis patients) may reduce the absorption and efficacy of levothyroxine. The treating physician will perform more frequent thyroid function tests (see also section "Warnings and precautions").
• Bile acid-binding agents: Colesevelam (a drug used to reduce high cholesterol levels) binds levothyroxine, thereby reducing its intestinal absorption. Therefore, Letrox should be taken at least 4 hours before colesevelam.
• Antacids containing aluminum, iron-containing drugs, calcium-containing drugs: Letrox should be taken at least 2 hours before antacids containing aluminum (antacids, sucralfate), iron-containing drugs, or calcium-containing drugs, as these may reduce intestinal absorption of levothyroxine.
• Propylthiouracil, glucocorticosteroids, beta-blockers (especially propranolol): Propylthiouracil (used in hyperthyroidism), glucocorticosteroids ("cortisone"), and beta-blockers (drugs slowing heart rate and reducing blood pressure) may reduce the efficacy of Letrox.
• Amiodarone and iodine-containing contrast agents: Amiodarone (used in cardiac arrhythmia treatment) and iodine-containing contrast agents (mainly used in X-ray diagnostics) may, due to their high iodine content, induce both hypothyroidism and hyperthyroidism. Particular attention should be paid to patients with nodular goiter, in whom undiagnosed autonomous thyroid nodules releasing hormones uncontrollably may be present. If necessary, the treating physician will adjust the Letrox dose.
• Salicylates, especially doses above 2 g per day (antipyretic and analgesic drugs).
• Dicoumarol (anticoagulant).
• Furosemide (diuretic) in high doses (250 mg).
• Clofibrate (a drug reducing elevated blood lipid levels).
• Contraceptives and drugs used in hormone replacement therapy:

Oral contraceptives containing estrogens ("birth control pills") and postmenopausal hormone replacement therapy may increase the requirement for levothyroxine.

• Sertraline, chloroquine / proguanil: Sertraline (used in depression treatment) and chloroquine and proguanil (used in malaria and rheumatoid arthritis treatment) may reduce levothyroxine efficacy.
• Rifampicin, carbamazepine, phenytoin, barbiturates, St. John's wort-containing products: Rifampicin (antibiotic), carbamazepine (used in epilepsy treatment), phenytoin (used in epilepsy and cardiac arrhythmias), barbiturates (used in epileptic seizures, anesthesia; some sleeping pills), and St. John's wort-containing products (herbal remedy) may reduce levothyroxine efficacy.
• Protease inhibitors (drugs used in HIV and chronic hepatitis C virus infection treatment): The doctor should closely monitor clinical symptoms and thyroid function in patients taking levothyroxine concomitantly with protease inhibitors (lopinavir, ritonavir). Concurrent use of levothyroxine with lopinavir and/or ritonavir may reduce its efficacy.
• Tyrosine kinase inhibitors (drugs used in cancer treatment): The doctor should closely monitor clinical symptoms and thyroid function in patients taking levothyroxine concomitantly with tyrosine kinase inhibitors (e.g. imatinib, sunitinib, sorafenib, motesanib). Levothyroxine efficacy may be reduced; the doctor may adjust the dose if necessary.
• Semaglutide: If the patient is taking levothyroxine at the same time as semaglutide (antidiabetic drug), this may affect levothyroxine levels, and the doctor may recommend monitoring thyroid hormone levels and adjusting the Letrox dose.
• Orlistat: Orlistat (used in obesity treatment) may reduce levothyroxine absorption.
• Biotin (also known as vitamin H, vitamin B7, or vitamin B8): If the patient is currently or recently taking biotin, they must inform the doctor or laboratory staff before undergoing thyroid hormone laboratory tests. Biotin may affect laboratory test results (see "Warnings and precautions").

Letrox with food and drink

Do not take Letrox with food, especially diets rich in calcium (e.g. milk and dairy products), as this may significantly reduce levothyroxine absorption.

In patients on a soy-containing diet, the doctor will monitor thyroid hormone levels in blood more frequently. During and after such a diet, dose adjustment of Letrox by the doctor may be necessary, as soy-containing products interfere with levothyroxine absorption in the intestines, thereby reducing its efficacy.

Do not take Letrox with coffee, as this may reduce intestinal absorption of levothyroxine and thus reduce its efficacy. After taking Letrox, wait at least 30 minutes to 1 hour before drinking coffee. Patients taking levothyroxine are advised not to change their coffee-drinking habits without checking and monitoring levothyroxine levels by the treating physician.

Pregnancy, breastfeeding and fertility

If the patient is pregnant or breastfeeding, suspects she may be pregnant, or plans to become pregnant, she should consult a doctor or pharmacist before using this medicine.

Adequate thyroid hormone therapy is particularly important for the health of both mother and fetus during pregnancy and breastfeeding. Therefore, treatment must be continued uninterrupted under medical supervision.

Despite widespread use of levothyroxine during pregnancy, any negative impact on pregnancy or on fetal or newborn health remains unknown.

If the patient is breastfeeding, levothyroxine should be continued as recommended by the doctor.

Even when taking high doses of levothyroxine during breastfeeding, the amount transferred into breast milk is very small.

Thyroid function should be monitored both during and after pregnancy, as dose adjustment by the doctor may be necessary during pregnancy.

During pregnancy, Letrox must not be used simultaneously with antithyroid drugs.

Thyroid suppression testing must not be performed in pregnant or breastfeeding women.

Hypothyroidism or hyperthyroidism may affect fertility.

When treating patients with hypothyroidism, the Letrox dose should be adjusted based on laboratory test results, as an insufficient dose may fail to correct hypothyroidism, while overdosing may lead to hyperthyroidism.

Driving and operating machinery

No studies have been conducted on the effect of Letrox on the ability to drive vehicles or operate machinery.

Letrox contains sodium

The medicine contains less than 1 mmol (23 mg) of sodium per tablet; therefore, the medicine is considered "sodium-free".

3. How to use Letrox

This medicine should always be taken exactly as prescribed by your doctor. If in doubt, consult
your doctor or pharmacist.
Your doctor will determine the daily dose for each patient based on clinical evaluation and
laboratory tests.
Dosage
Letrox is available in tablets with different amounts of active substance (25–150 micrograms of
sodium levothyroxine), meaning that most patients will take one tablet per day.
Your doctor will prescribe tablets with the appropriate amount of active substance when starting
treatment and when increasing the dose.
Depending on symptoms, your doctor will adjust the dose according to the following recommendations:

• In the treatment of hypothyroidism, the initial dose for adult patients is 25–50 micrograms of sodium levothyroxine per day. Your doctor may recommend increasing the dose by 25–50 micrograms of sodium levothyroxine at intervals of 2–4 weeks until reaching a daily dose of 100–200 micrograms of sodium levothyroxine.
• For prevention of goiter recurrence after its removal and in the treatment of benign goiter, the daily dose is 75–200 micrograms of sodium levothyroxine.
• As an adjunct in the treatment of hyperthyroidism in combination with antithyroid agents, the daily dose is 50–100 micrograms of sodium levothyroxine.
• After surgical removal of the thyroid gland due to malignant thyroid tumors, the daily dose is 150–300 micrograms of sodium levothyroxine.
• In tests assessing thyroid function during thyroid suppression testing, the daily dose is 200 micrograms of sodium levothyroxine taken for 14 days until radiological examination (scintigraphy) is performed.

A lower dose of thyroid hormone may also be appropriate.
Use in children and adolescents
The maintenance dose during long-term treatment of (congenital or acquired) hypothyroidism is usually 100 to 150 micrograms of sodium levothyroxine per m² body surface area per day.
In newborns and infants with congenital hypothyroidism, prompt initiation of treatment is particularly important to achieve normal development. The recommended initial dose is 10 to 15 micrograms of sodium levothyroxine per kg body weight per day for the first 3 months. Thereafter, your doctor will individually adjust the daily dose based on clinical findings (particularly blood levels of thyroid hormones and TSH).
In children with acquired hypothyroidism, the recommended initial dose is 12.5–50 micrograms of sodium levothyroxine per day. Your doctor will gradually increase the daily dose every 2–4 weeks until the appropriate replacement dose is achieved. For this purpose, your doctor will particularly monitor blood levels of thyroid hormones and TSH.
Elderly patients, patients with ischemic heart disease, patients with hypothyroidism
In elderly patients, patients with ischemic heart disease, and patients with severe or long-standing hypothyroidism, thyroid hormone therapy should be initiated with particular caution (a low initial dose, which should then be increased slowly over long intervals, with frequent monitoring of thyroid hormone concentrations and TSH levels).
Patients with low body weight and patients with large goiter
Experience indicates that lower doses are also sufficient in patients with low body weight and in patients with large goiter.
Splitting tablets
Tablets may be divided into equal doses.
Place the tablet on a flat, hard surface with the scored side facing up. Pressing the tablet with a finger will split it into two halves.

Method of administration
The full daily dose should be taken in the morning with a large amount of fluid, preferably a glass of water, on an empty stomach, at least half an hour before breakfast. The active substance is better absorbed on an empty stomach than before or after meals.
Children should receive the total daily dose at least half an hour before the first meal. Tablets may also be dissolved in an appropriate amount of water (10–15 ml), and the resulting suspension (tablets must be dissolved immediately before each administration) may be given with a small additional amount of liquid (5–10 ml).
Duration of treatment
Letrox is usually taken for life in cases of hypothyroidism and after surgical removal of the thyroid gland due to malignant thyroid tumors. In the treatment of benign goiter and prevention of goiter recurrence, treatment may last several months or years, and even for life.
In adjunctive therapy for hyperthyroidism, Letrox should be taken for as long as antithyroid agents are used. Treatment of benign goiter with normal thyroid function should last from 6 months to 2 years. If treatment with Letrox does not produce the expected effect within this time, your doctor will consider alternative treatment options.
Your doctor decides on the duration of treatment.
Taking a higher than recommended dose of Letrox
If a higher dose than recommended is taken, contact your doctor immediately.
Symptoms of overdose may include those of hyperthyroidism.
Symptoms of overdose are described in section 4. "Possible side effects".
Missed dose of Letrox
If a patient takes too low a dose or misses a dose, they should not take a double dose to make up for the missed dose. Continue taking the medicine as prescribed by your doctor.
Stopping treatment with Letrox
To achieve the desired therapeutic effects, Letrox must be taken regularly at the dose prescribed by your doctor.
Under no circumstances should the dose be changed, treatment interrupted, or discontinued prematurely without consulting your doctor, as symptoms may recur.
If you have any further questions about the use of this medicine, consult your doctor or pharmacist.

4. Possible adverse reactions

Like all medicines, this medicine can cause adverse reactions, although not everyone will experience them.

Hypersensitivity to the active substance or any of the other components of Letrox

In case of hypersensitivity to levothyroxine or any of the other components of Letrox, allergic skin reactions and allergic reactions involving the respiratory system (either immediately or within a few days of taking the medicine) may occur, which may be life-threatening. These symptoms may include rash, itching, difficulty breathing, shortness of breath, swelling of the face, lips, throat, or tongue. Immediate contact with a doctor or healthcare professional is required, or go immediately to the nearest hospital emergency department.

Intolerance to the administered dose, overdose

In individual cases, when the recommended dose is not tolerated or when the medicine has been overdosed, particularly when the dose has been increased too rapidly at the beginning of treatment, typical symptoms of hyperthyroidism may occur.

Very common: may affect more than 1 in 10 patients

• Palpitations
• Insomnia
• Headache

Common: may affect up to 1 in 10 patients

• Fast heartbeat (tachycardia)
• Nervousness

Rare: may affect up to 1 in 1,000 patients

• Increased intracranial pressure (especially in children)

Frequency not known: cannot be estimated from the available data

• Hypersensitivity
• Heart rhythm disorders
• Chest pain with a feeling of pressure (angina pectoris)
• Skin allergic reactions (e.g. angioedema [difficulty breathing or swelling of the face, lips, throat, or tongue], rash, urticaria)
• Anxiety
• Muscle weakness, muscle cramps
• Osteoporosis during long-term use of high doses of levothyroxine, particularly in postmenopausal women
• Feeling of warmth, intolerance to high temperature, circulatory collapse in premature infants with low birth weight (see section 2 "Warnings and precautions")
• Menstrual disturbances
• Diarrhea
• Vomiting
• Nausea
• Weight loss
• Tremor
• Excessive sweating
• Fever

If adverse reactions occur, inform your doctor. The doctor will decide whether the daily dose should be reduced or whether treatment should be interrupted for several days. Once the adverse reactions have subsided, the doctor may cautiously resume treatment with an adjusted dose.

Reporting of adverse reactions

If any adverse symptoms occur, including any adverse symptoms not listed in this leaflet, inform your doctor, pharmacist, or nurse. Adverse reactions can be reported directly to the Department of Monitoring Adverse Reactions of Medicinal Products at the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Al. Jerozolimskie 181C
02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl

Adverse reactions can also be reported to the marketing authorization holder.
Reporting adverse reactions helps to provide more information on the safety of this medicine.

5. How to store Letrox

Keep this medicine out of sight and reach of children.
Do not use this medicine after the expiry date stated on the blister and outer packaging following the abbreviation "EXP". The expiry date refers to the last day of the stated month.
Do not store above 30°C. Keep in the original blister to protect from light.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This helps protect the environment.

6. Contents of the pack and other information

What Letrox contains
The active substance in this medicine is sodium levothyroxine.
Letrox 50: Each tablet contains 53.2 – 56.8 micrograms of sodium levothyroxine x H\₂O (equivalent to 50 micrograms of sodium levothyroxine).
Letrox 75 micrograms: Each tablet contains 79.8 – 85.2 micrograms of sodium levothyroxine x H\₂O (equivalent to 75 micrograms of sodium levothyroxine).
Letrox 100: Each tablet contains 106.4 – 113.6 micrograms of sodium levothyroxine x H\₂O (equivalent to 100 micrograms of sodium levothyroxine).
Letrox 125 micrograms: Each tablet contains 133.0 – 142.0 micrograms of sodium levothyroxine x H\₂O (equivalent to 125 micrograms of sodium levothyroxine).
Letrox 150: Each tablet contains 159.6 – 170.4 micrograms of sodium levothyroxine x H\₂O (equivalent to 150 micrograms of sodium levothyroxine).

Other ingredients are:
Cysteine hydrochloride monohydrate (partially present in the tablet as cystine), microcrystalline cellulose, maize starch, pregelatinized starch, magnesium oxide, light talc.

What Letrox looks like and contents of the pack
Letrox is a white to beige, round, slightly convex tablet with a division line on one side. The tablet can be divided into equal doses.
Pack sizes contain 25, 50, 84 or 100 tablets.
Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer
BERLIN-CHEMIE AG
Glienicker Weg 125
12489 Berlin, Germany

For further information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Berlin-Chemie/Menarini Polska Sp. z o.o.
Tel.: +48 22 566 21 00
Fax: +48 22 566 21 01